Skip to content

Bangladesh Vitamin E and Selenium Trial

Bangladesh Vitamin E and Selenium Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00392561
Acronym
BEST
Enrollment
7000
Registered
2006-10-26
Start date
2006-04-01
Completion date
2021-08-19
Last updated
2023-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-melanoma Skin Cancer

Brief summary

The purpose of this study is to evaluate whether selenium and/or vitamin E are effective in preventing non-melanoma skin cancers.

Interventions

DIETARY_SUPPLEMENTSelenium

200 ug Selenium daily

DIETARY_SUPPLEMENTvitamin E

100 mg Vitamin E daily

Sponsors

Columbia University
CollaboratorOTHER
Dartmouth-Hitchcock Medical Center
CollaboratorOTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
University of Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Manifest arsenic skin lesions (melanosis, leucomelanosis, or keratosis) * Aged 25 to 65 years * Permanent resident of study area

Exclusion criteria

* Pregnancy * Clinically too ill (enlarged spleen or liver) * Presence of gangrene * Cancer

Design outcomes

Primary

MeasureTime frame
Skin CancerIncidence during the 6-year study period

Secondary

MeasureTime frame
MortalityOccurrence during the 6-year study period
DiabetesIncidence within 6-year study period

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026